2020 年第 5 期 第 15 卷

利福平胶囊（Ⅱ）治疗肺结核的临床效果及对患者肝功能的影响

Effect of rifampicin capsules (Ⅱ) on tuberculosis and liver function

作者：陶磊1;赵志忍2;张乐天3

英文作者：Tao Lei1 Zhao Zhiren2 Zhang Letian3

单位：1河北省胸科医院结核五科，石家庄050041；2河北省胸科医院急诊科，石家庄050041；3河北省胸科医院呼吸二科，石家庄050041

英文单位：1The 5th Department of Tuberculosis Hebei Chest Hospital Shijiazhuang 050041 China; 2Department of Emergency Hebei Chest Hospital Shijiazhuang 050041 China; 3the 2nd Department of Respiratory Hebei Chest Hospital Shijiazhuang 050041 China

关键词：肺结核；利福平胶囊（Ⅱ）；疗效；肝功能

英文关键词：Pulmonarytuberculosis；Rifampicincapsules (Ⅱ)；Curativeeffect；Liverfunction

• 摘要：

• 目的 探讨利福平胶囊（Ⅱ）治疗肺结核的临床效果及对患者肝功能的影响。方法 选取2018年1—11月河北省胸科医院初诊治肺结核患者80例，采用随机数字表法分为观察组和对照组，各40例。2组均选用规范2HRZE/4HR治疗，其中对照组给予利福平胶囊治疗，观察组给予利福平胶囊（Ⅱ）治疗。比较2组痰菌转阴率、病灶吸收及空洞变化情况，分析治疗15 d、1个月、2个月末患者血清丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）及直接胆红素（DBIL）等肝功能指标变化。比较2组临床效果和不良反应情况。结果 治疗1、2个月后，观察组痰菌转阴率均明显高于对照组［77.5%（31/40）比62.5%(25/40)、90.0%（36/40）比77.5%（31/40）］，病灶吸收情况和空洞闭合情况均明显优于对照组，差异均有统计学意义（均P＜0.05）。治疗6个月后，观察组治疗总有效率明显高于对照组［97.5%（39/40）比87.5%（35/40）］，差异有统计学意义（P=0.017）。治疗15 d后、1个月及2个月后，观察组血清ALT、AST、DBIL水平均低于对照组，差异均有统计学意义（均P＜0.05）。治疗过程中，观察组不良反应发生率明显低于对照组，差异有统计学意义（P＜0.001）。结论利福平胶囊（Ⅱ）治疗初诊治肺结核的疗效显著，安全性高，可有效改善患者临床症状，降低肝功能损伤程度。

• Objective To investigate the clinical effect of rifampicin capsule (Ⅱ) on tuberculosis and liver function. Methods Eighty patients with pulmonary tuberculosis were enrolled from Hebei Chest Hospital from January to November 2018. The patients were randomly divided into two groups, with 40 cases in each group. Two groups were given 2HRZE/4HR treatment, while the control group was given rifampicin capsules and the observation group was given rifampicin capsules (Ⅱ). The sputum negative conversion rate, focus absorption and cavity changes in two groups were compared. The changes of serum alanine aminotransferase (ALT), aspartate  aminotransferase (AST) and direct bilirubin (DBIL) were analyzed. The clinical effects and adverse reactions were compared between the two groups. Results After 1， 2 months of treatment, the sputum negative conversion rates in observation group were significantly higher than those in control group［77.5%（31/40） vs 62.5%(25/40), 90.0%（36/40） vs 77.5%（31/40）］(P＜0.05). The lesion absorption and cavity closure in observation group were also better than those in control group (P＜0.05). The total effective rate of observation group after 6 months treatment was significantly higher than that in control group［97.5%（39/40） vs 87.5%（35/40）, P=0.017］. After 15 d, 1 and 2 months of treatment, all liver function indexes in observation group were lower than those in control group (P＜0.05). The incidence of adverse drug reactions in observation group was significantly lower than that in control group(P＜0.001). ConclusionRifampicin capsules (Ⅱ) is effective and safe in treating pulmonary tuberculosis; it can effectively improve the clinical symptoms and reduce the degree of liver function damage.